Literature DB >> 1711631

Dual mechanism of the relaxing effect of nicorandil by stimulation of cyclic GMP formation and by hyperpolarization.

W R Kukovetz1, S Holzmann, C Braida, G Pöch.   

Abstract

In addition to previous results from our laboratory showing that nicorandil relaxed vascular smooth muscle by increasing cyclic GMP levels, it was shown to activate K-channels as well, an effect that also leads to relaxation. In the present study, we attempted to differentiate quantitatively between these two effects in isolated bovine coronary artery strips with simultaneous isotonic measurement of length and radioimmunoassay (RIA) determination of cyclic GMP. When the strips were contracted by the thromboxane A2 analogue U 46619 (1 microM) with 10 microM methylene blue added, nicorandil produced 30-50% relaxation without significant changes in cyclic GMP. When in U 46619-contracted strips the hyperpolarizing effect of nicorandil was suppressed by increasing extracellular K+ to 80.4 mM (30-fold), nicorandil caused only 52% relaxation, whereas cyclic GMP increases were not significantly suppressed. Quantitative separation of both mechanisms of relaxation by nicorandil was further achieved through calculation of the cyclic GMP-mediated component from a correlation between increases in cyclic GMP and percentage of relaxation as produced by nicorandil under conditions of inhibited hyperpolarization, i.e., in strips contracted with 1 microM U 46619 or 26.8 mM K+ (10-fold) and exposed to either 30-fold K+ or 10 mM Ba2+. Under both conditions, similar correlations between cyclic GMP and relaxation were obtained. Because U 46619, in addition to its contractile effect, partially antagonized the relaxation by nicorandil without changing cyclic GMP, the correlation was corrected for this effect and indicated a participation of cyclic GMP in the overall relaxant response of approximately 30-40% at low and less than or equal to 80-90% at high concentrations of nicorandil.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1711631     DOI: 10.1097/00005344-199104000-00016

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  15 in total

1.  Responses to vasodilator drugs on pulmonary artery preparations from pulmonary hypertensive rats.

Authors:  J C Wanstall; S R O'Donnell
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

2.  Safer stress tests for myocardial perfusion imaging.

Authors:  Sang-Geon Cho; Zeenat Jabin; Henry Hee-Seung Bom
Journal:  J Nucl Cardiol       Date:  2017-10-16       Impact factor: 5.952

Review 3.  Potassium channel openers in myocardial ischaemia: therapeutic potential of nicorandil.

Authors:  A H Gomma; H J Purcell; K M Fox
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  [Nicorandil: acute hemodynamic effects of 2 different oral doses of a potassium channel opener in patients with coronary heart disease].

Authors:  C Bickel; H J Rupprecht; A Tyrtania; J Rörig; J Meyer
Journal:  Med Klin (Munich)       Date:  1999-02-15

Review 5.  Use of nicorandil in cardiovascular disease and its optimization.

Authors:  Shigeo Horinaka
Journal:  Drugs       Date:  2011-06-18       Impact factor: 9.546

6.  Effects of nicorandil on the reduction of BNP levels in patients with chronic kidney disease.

Authors:  Tomonori Kimura; Harumi Kitamura; Kazunori Inoue; Noritaka Kawada; Isao Matsui; Yasuyuki Nagasawa; Yoshitsugu Obi; Maki Shinzawa; Yasuhiko Sakata; Takayuki Hamono; Hiromi Rakugi; Yoshitaka Isaka
Journal:  Clin Exp Nephrol       Date:  2011-08-23       Impact factor: 2.801

7.  Nicorandil induces late preconditioning against myocardial infarction in conscious rabbits.

Authors:  Xian-Liang Tang; Yu-Ting Xuan; Yanqing Zhu; Gregg Shirk; Roberto Bolli
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-12-18       Impact factor: 4.733

8.  Protection by nicorandil against the dysfunction of the central vagal baroreflex system following transient global cerebral ischaemia in dogs.

Authors:  J Kurihara; N Ochiai; H Kato
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

9.  Mechanism of the vasodilatory action of nicorandil on coronary circulation in dogs.

Authors:  I Nakae; L Quan; K Hashimoto; Y Sugimoto; T Tsutamoto; M Kinoshita
Journal:  Cardiovasc Drugs Ther       Date:  1994-02       Impact factor: 3.727

10.  Vasorelaxant mechanism of KRN2391 and nicorandil in porcine coronary arteries of different sizes.

Authors:  A Miwa; S Kaneta; K Motoki; Y Jinno; H Kasai; Y Okada; H Fukushima; N Ogawa
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.